Helena A Yu
ECOG-ACRIN Cancer Research Group · Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Helena A Yu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:52 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT04181060 · Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerNational Cancer Institute (NCI) · recruiting · Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma · principal investigator
- Ph2NCT03944772 · Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)AstraZeneca · active not recruiting · Non-Small Cell Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:52 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Drivers of histologic transformation in EGFR-mutant lung cancerR01CA264078 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2021 to 2025 · $404,888 awarded in 2025Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026Named on NCT04181060
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 09:52 UTC. The ranking covers the 200 most relevant of 20 PubMed records, and a shared surname and initials can bring in a namesake. All 20 on PubMed
- Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.Clin Cancer Res · 2016312 citationsRCR 9.8
- Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer.Cancer Discov · 2022270 citationsRCR 17.1
- 239 citationsRCR 20.3
- 76 citationsRCR 3.1
- Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor.Clin Lung Cancer · 201855 citationsRCR 1.8
- Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC.Ann Oncol · 202449 citationsRCR 4.4
- Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung Cancer.Clin Cancer Res · 202145 citationsRCR 2.2
- Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers.Cold Spring Harb Mol Case Stud · 201931 citationsRCR 0.9
- Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.Nat Commun · 202128 citationsRCR 1.4
- A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations.Clin Cancer Res · 201723 citationsRCR 0.7